Bracco’s Blue Earth buy boosts Syncona
Syncona might have hoped for a bigger payday with the prostate imaging specialist, but it has plenty more irons in the fire.
Price fixing case caps a terrible week for generics
Shares in generics firms tumble in the wake of a huge lawsuit in the US alleging industry-wide price fixing, signalling many more years of pain for this sector.
J&J’s Auris buy looks like a Verb swerve
Johnson & Johnson’s $3.4bn move for the robotic surgery specialist Auris Health could be bad news for its Verb Surgical joint venture.
In, out, in, out, Glaxo shakes consumer health about
Earlier this year Glaxosmithkline looked to be going all-in for consumer health domination, but today it moved to leave the space entirely and focus on the thing that…
Neurostimulation sham scuppers Mainstay
Mainstay Medical still hopes for US approval of its Reactiv8 device for chronic back pain despite trial failure.